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ABSTRACT 
PROSPECTIVE TRIAL COMPARING TOPICAL STEROID APPLICATION TO WET  
VERSUS DRY SKIN IN CHILDREN WITH ATOPIC DERMATITIS. 
 
Lucinda S. Liu, Yanna Kang, and Richard J. Antaya.  
Department of Dermatology, Yale University School of Medicine, New Haven, CT. 
 
The aim of this study was to determine whether “soak and smear,” a technique where 
hydration via a 10-minute soak in lukewarm plain water followed by topical corticosteroid 
application to wet skin, is efficacious for the treatment of atopic dermatitis in pediatric 
patients.  A randomized, investigator-blinded study was conducted with 45 patients, 4 
months to 16 years of age, with moderate to severe atopic dermatitis.  All patients received 
fourteen days of topical corticosteroid ointment and were randomly assigned to either apply 
the corticosteroid on wet skin via the soak and smear method (treatment arm) or on dry skin 
(control arm).  The primary outcome measure was percentage improvement by Eczema 
Area and Severity Index (EASI) score.  Atopic dermatitis severity of patients who applied 
corticosteroid ointment to wet skin via soak and smear improved 84.8% by EASI score, 
whereas atopic dermatitis severity of patients who applied corticosteroid ointment to dry skin 
improved 81.4% by EASI score.  There was no statistical difference between the two groups 
(p-value = 0.85).  The use of corticosteroid application to pre-hydrated, wet skin is not more 
efficacious than corticosteroid application to dry skin in pediatric patients with moderate to 
severe atopic dermatitis. 
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INTRODUCTION 
Atopic dermatitis (AD), synonymous with ‘atopic eczema’ and colloquially referred to as 
‘eczema’, is a chronic, inflammatory skin disease that primarily affects infants and children.  
AD is one component of an atopic triad, which includes asthma and allergic rhinitis.  AD is 
thought to have a complex pathogenesis involving genetic predisposition leading to a 
dysfunctional skin barrier and immune dysregulation, and environmental factors that lead to 
clinical presentation.  The hallmark of AD lies in its pruritic nature, which contributes to much 
of the disease burden shouldered by patients and their families. 
Epidemiology 
AD is mainly a disease of childhood and is thought to have a prevalence of 10-20% in 
children and 3-10% in adults in the United States depending on diagnostic criteria (1, 2).  
The most recent comprehensive United States study derived from the 2003 National Survey 
of Children’s Health reported a point prevalence of AD in children 0-17 years of age ranging 
from 8.7% to 18.1% by state with the nationwide average being 10.7%. (1) These results are 
consistent with other United States-based epidemiological studies (3, 4).  The wide range of 
prevalence suggests that environmental influences may play a role in disease expression, 
and indeed the prevalence was noted to be higher in urban areas (1).  AD may affect 
individuals of all ages, but most commonly begins in childhood: in 60% of cases it begins in 
the first year of life, and in 85% of cases it begins by 5 years of age (5).   
Clinical Manifestations and Diagnosis 
Typically, AD is classified into three age-related stages: infantile, childhood, and adulthood.  
The infantile form, which occurs in children up to 2 years of age, is typified by acute 
inflammation, which presents as intensely pruritic, red, weeping papules and plaques often 
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accompanied by vesicles, scale, and serous crust on the cheeks and extensor surfaces.  In 
school age children, AD is typified by chronic inflammation, migrates to flexor surfaces, and 
presents with less exudation and more hyperkeratotic plaques and papules.  It remains 
intensely pruritic and increased scratching and rubbing result in lichenification and scale.  In 
adults, AD presents similarly to childhood AD, especially in those who had AD in childhood; 
however, AD in adults has more of a tendency to localize to the hands and eyelids. 
In 2003, The American Academy of Dermatology Consensus Conference on Pediatric 
Atopic Dermatitis published a set of clinical criteria required for the diagnosis of AD.  The 
diagnosis of AD depends on the exclusion of other similar red, scaly pruritic conditions such 
as scabies, seborrheic dermatitis, allergic or irritant contact dermatitis, ichthyoses, 
cutaneous T-cell lymphoma, psoriasis, and immune deficiency diseases (6).  After the 
exclusion of other dermatologic conditions, the diagnosis is based on essential, important, 
and associated features listed in Table 1. 
Table 1: Diagnostic Guidelines for Atopic Dermatitis (6) 
Essential features  
must be present 
Pruritus 
Eczematous changes 
• typical morphology:  
o facial, neck, and extensor lesions in infants and children 
o flexor lesions in any age group 
o sparing of the groin and axillary regions 
• age-specific distributions 
Chronic or relapsing course 
Important features  
seen in most cases 
Early age onset 
Personal/family history of atopy (IgE reactivity) 
Xerosis 
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Table 1: Diagnostic Guidelines for Atopic Dermatitis, continued 
Associated features 
seen often, but 
nonspecific 
Atypical vascular responses (facial pallor, delayed blanch response) 
Keratosis pilaris 
Pityriasis alba 
Hyperlinear palms 
Ichthyosis 
Ocular/periorbital changes 
Perioral/periauricular lesions 
Perifollicular accentuation 
Lichenification 
Prurigo lesions 
 
Burden of Disease 
Because of its high prevalence and non-life threatening status, health care professionals 
frequently view AD as a minor skin ailment that resolves with age.  Yet, living with AD can 
have a profound impact on quality of life.  Both the physical discomfort of AD as well as the 
psychological distress have been shown by numerous studies to negatively impact patients’ 
health-related quality of life.  In fact, when Beattie et al compared the quality of life in 
children with AD against children with other skin diseases and children with other chronic 
childhood diseases using a standardized questionnaire, the Children’s Life Quality Index©, 
they found that generalized AD impaired quality of life more than diabetes, epilepsy, asthma, 
cystic fibrosis, and renal disease.  In fact, AD scored higher than other common childhood 
diseases except cerebral palsy (7). 
Although this may seem surprising at first, the physical discomfort of AD, consisting mainly 
of intense pruritus, and its associated illnesses, such as other atopic diseases as well as 
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bacterial and viral super-infection can lead to restriction of daily activities, limited 
participation in sports, and decreased social time.  Given that AD lesions in children 
predominantly occur on easily visible areas, like the face, posterior neck, extremities, hands, 
and feet, the cosmetic consequences of this rash can hinder the development of strong, 
positive social relations.  Other children and teachers may see the weeping red rash, scaly 
lichenified skin, and/or the excessive scratching of children with AD and alienate them for 
fear of infection.  Embarrassment, comments, teasing and bullying cause poor self-image 
and self-esteem.  In older children, AD lesions may lead to anxiety and depression.   
The intense pruritus of AD leads to sleep disturbances, which then leads to daytime 
drowsiness and an increased struggle to remain focused in the classroom (8).  Families, 
especially parents or caregivers, are substantially affected by sleep deprivation.  On 
average, parents lose 2.7 hours of sleep per night during an AD flare (8).  Sleeplessness in 
turn can hinder caregiver work performance and coping skills in the home.  Additionally, the 
burden of providing treatment, which includes complicated topical regimens, increased 
laundry, house cleaning, and restrictions on travel cause stress, anxiety, frustration, and 
hopelessness amongst caregivers.  Dysfunctional parent-child relationships occur more 
frequently with intractable eczema, and may play a role in altering child behavior (9).  
Moreover, there is a strong correlation between AD and mental health problems in children.  
Children with AD show increased emotional difficulties, conduct problems, and 
hyperactivity/inattention that may persist even after clearance of their AD (10).   
Theory of Pathogenesis 
Traditionally, it had been postulated that a defective epidermal permeability barrier and a 
proclivity to develop secondary cutaneous infections, two hallmarks of AD, are caused by a 
hyperactive and dysregulated immune system.  However, in 1999 two independent groups 
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proposed the reverse: they postulated that clinical manifestation of AD develops from a 
primary disruption of the epidermal barrier (11, 12).  Disruption of the natural barrier 
properties of skin, which could be caused by genetic defects, trauma, infection, and altered 
pH, exposes cutaneous immune cells to antigens and irritant agents, leading to release of 
proinflammatory cytokines and causing cutaneous inflammation (13). 
A strong genetic basis for the development of AD is suggested by twin studies showing that 
if one monozygotic twin develops AD, the other has an 80% rate of developing AD, whereas 
the rate is only 20% in dizygotic twins (14, 15).  Patients with AD have been shown to have 
an array of genetically determined risk factors that impair skin barrier function.  To date, the 
best-studied gene associated with the development of AD is FLG, which encodes for 
filaggrin (16).  In normal skin, formation of the cornified cell envelope begins with the 
dephosphorylation and cleavage of profilaggrin into functional filaggrin monomers.  Filaggrin 
facilitates the collapse and flattening of keratin filaments, which is essential for keratinocyte 
terminal differentiation.  Loss-of-function mutations in FLG have been found in 20-50% of 
European children with AD as compared to 10% of the general European population, with 
more than half of children with moderate to severe AD possessing a mutation (16, 17).   
In addition to decreasing structural integrity of the cornified envelope, the barrier function of 
the stratum corneum can be damaged by reducing epidermal hydration.  A lipid molecule, 
ceramide, is an essential component in the generation of natural moisturizing factor.  
Ceramide plays a role in retaining water and its decreased presence in elderly individuals is 
the main reason for xeroderma of the elderly.  In AD, upregulation of sphingomyelin 
deacylase activity precludes functional ceramide, resulting in the inability of stratum 
corneum to hold onto water.  The stratum corneum is composed of proteins that promote 
water absorption and lipids that prevent water loss through the epidermis.  Both are 
necessary for epidermal barrier function, and transepidermal water loss results in xerotic 
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skin, which secondarily causes pruritus prompting scratching, which causes trauma to the 
skin.  Damage to the stratum corneum promotes the release of proinflammatory mediators, 
leading to more pruritus, and inducing the “itch-scratch” cycle notorious to AD. 
Compromise of the skin barrier in turn increases exposure of the immune system to 
environmental antigens, which is postulated to play a major role in sensitizing and 
upregulating the immune system in AD.  Studies have shown that FLG mutations 
predispose to childhood asthma only in children who first develop AD.  In fact, one study has 
shown that children with FLG mutations who develop both AD and food allergy have a 100% 
positive predictive value for developing asthma (18). This progression of first developing AD 
and food allergy, then asthma, and finally allergic rhinitis in childhood is known as the atopic 
march.  The main theory behind the atopic march is one based on the observation that more 
severe AD and skin barrier disruption correlates with higher serum IgE levels.  In fact, 
sustained exposure to antigens through a defective skin barrier leads to a local increase in 
T-helper 2 (Th2) infiltrate.  Th2 cells release cytokines such as IL-4, which further damage 
the dysfunctional barrier, worsening the cutaneous disease (19). Furthermore, this local 
response later becomes a systemic immune hypersensitization and leads to the 
development of asthma and allergic rhinitis. 
Treatment Options 
Treatment for AD consists of an exhaustive assembly of options that address barrier 
dysfunction and cutaneous inflammation through either supportive/preventive measures or 
through pharmacologic therapy.   
The level of success attained through supportive care for AD is directly related to how much 
education patients and their families receive about AD (20).  Patients and their families need 
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to be educated on what environmental factors may trigger AD in order to minimize their 
contact with them.  Triggers will vary among patients, but common trigger factors include 
alkaline soaps, dust mites, animal dander, wool or rough synthetic fibers, food allergens 
found in eggs, peanuts, and cow’s milk (21).  Effective dust mite reduction in the bedroom 
through high-filtration vacuuming, using protective bedding, and benzyl tannate spray has 
shown to improve AD modestly (22).  An excellent skin care regimen aimed at improving 
and preventing xerosis is first-line therapy for AD.  Generally, the use of emollients 
consisting of ointments and creams, which contain more lipids, are more effective for skin 
hydration and improving barrier function than lotions, which are water-based (6).  Optimal 
bathing technique should also be explained as it can be helpful if done correctly: alkaline 
soaps should be replaced with mild non-alkaline cleansers; cleansers can be used sparingly, 
only focusing on the groin and axilla, where apocrine glands are found; and baths and 
showers should be with warm water, not hot water, which may increase inflammation and 
irritation.  Bubble baths and scented salts should be avoided.  After bathing, caregivers 
should gently pat the child dry with a towel taking care not to rub the skin, which can be 
thought of as scratching.  Immediately after towel drying, the liberal quantities of a 
moisturizer should be applied to avoid allowing moisture from evaporating off the skin. 
Oftentimes, supportive and preventative care is adequate at keeping AD at bay.  However, a 
stressful situation such as beginning a new school year may cause a child’s AD to flare.  In 
these circumstances, pharmacologic agents may be used to quickly gain control of a 
disease exacerbation.  Topical corticosteroids (see Table 2) are the first line of 
pharmacologic therapy, and they work through their anti-inflammatory, immunosuppressive, 
and vasoconstrictive actions (21).  During an exacerbation, they are usually applied twice 
daily, although certain formulations may be applied once daily. More potent corticosteroid 
ointments like fluocinonide may be used for lichenified plaques, whereas the mid-potency 
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preparation 0.1% triamcinolone acetonide is frequently prescribed for widespread whole-
body application, excluding intertriginous and facial areas.  Once control of AD has been 
achieved, topical corticosteroids may be tapered down to a mid potency preparation and 
applied twice weekly as a maintenance dose for children with moderate-severe disease.   
Table 2: Select Topical Corticosteroids Used in the Pediatric Population 
Potency (group) 
 
Generic 
 
Vehicle* 
 
Ultra high (I) Clobetasol propionate 0.05% 
Augmented betamethasone dipropionate 0.05% 
C, F, O, L 
O 
High (II) Fluocinonide 0.1% C 
Mometasone furoate 0.1% O 
Medium to high (III) Fluticasone propionate 0.005% O 
Triamcinolone acetonide 0.1% O 
Medium (IV and V) Prednicarbate 0.1% C 
Fluticasone propionate 0.05% C, L 
Mometasone furoate 0.1% C 
Low (VI) Alclometasone dipropionate 0.05% C, O 
Desonide 0.05% C, G, F, O 
Fluocinolone acetonide 0.01% C 
Least potent (VII) Hydrocortisone 1%, 2.5% O,C,L 
*C = cream; F = foam; G = gel; L = lotion; O = ointment 
Side effects of topical corticosteroids are well known with the most common one being skin 
atrophy due to their inhibition of collagen synthesis.  Higher potencies, occlusion, and areas 
of thinner skin like the face, neck, and intertriginous areas increase the risk of atrophic 
changes in the skin such as easy bruising, increased fragility, purpura, striae, and 
telangiectasia.  Other local adverse effects topical corticosteroids may cause are changes in 
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pigmentation, rosacea, acne, contact sensitization, cataracts, and glaucoma. Systemic 
adverse effects, while rare, include suppression of the hypothalamic pituitary-adrenal axis, 
Cushing disease, decreased growth rate, and reduced bone density (21). Although these 
potential adverse effects may dissuade healthcare providers from prescribing stronger 
topical corticosteroid formulations, it is important for a topical preparation of adequate 
potency to be selected for treatment, because long-term use of inadequately potent topical 
corticosteroids can be equally as harmful as briefly using highly potent corticosteroids and 
may not completely clear the disease (22). 
Immunocompetent children of at least two years of age with frequently flaring or persistent 
AD that would require continual topical corticosteroid application may be treated with topical 
calcineurin inhibitors (TCI) instead, because TCIs are not associated with skin atrophy or 
striae.  TCIs have been approved by the United States Food and Drug Administration (FDA) 
as second-line therapies for children with AD: tacrolimus for moderate-severe AD and 
pimecrolimus for mild-moderate AD.  In 2006, the FDA released a black box warning of the 
potential risk of cancer with the use of TCIs.  This theoretical possibility of malignancy 
warning was added based on two areas of concern.  High dose oral calcineurin inhibitors 
given as immunosuppression in transplant recipients had been associated with post-
transplant lymphoproliferative disorder and nonmelanoma skin cancer.  Additionally, mice 
and primates that were exposed to very high doses of oral calcineurin inhibitors (30-50 times 
higher levels of systemic calcineurin inhibitors than the recommended oral dosages in  
humans) developed lymphomas (23).  Prospective, long-term safety studies in both children 
and adults are ongoing for TCI treatment in AD.  Thus far, a 10-year prospective safety 
study of topical tacrolimus in children has not detected an increased incidence of lymphoma 
or nonmelanoma skin cancer in the 8,000 children that it has enrolled (24).   
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In AD that is refractory to topical treatments, systemic immunomodulatory therapies such as 
oral cyclosporine, methotrexate, azathioprine, and mycophenolate mofetil may be used.  
However, because of their more alarming side effect profiles, they should be reserved for 
short-term treatment of severe AD that has been recalcitrant to topical treatment.  Other 
alternative therapies include phototherapy, sedating antihistamines at bedtime to break the 
itch-scratch cycle, and antimicrobials for those with infected AD.  Phototherapy risks include 
sunburn and with long-term use, photo-aging and a theoretical risk of cutaneous 
malignancies.  
Because systemic treatments have such a high side effect profile, several adjunctive 
techniques have been described to increase the efficacy of standard topical treatments, 
including wet wraps and soak and smear.  The use of wet wraps have been studied in 
children with severe and/or refractory AD with considerable success (25, 26). The process of 
applying wet wraps involves first bathing, applying a topical steroid and/or emollient over the 
body, then wrapping the child first in damp cotton bandages or damp cotton pajamas, and 
finally in dry cotton bandages or pajamas before bed.  Wet wraps increase skin hydration, 
physically inhibit the ability to scratch, and increase penetration of topical corticosteroids by 
acting as an occlusive barrier.  However, wet wraps need to be applied carefully, as 
improper technique may result in maceration of the skin and secondary infections (21). 
There is much reluctance from families and providers to use wet wraps, because the 
wrappings are tedious to cut down to the correct size, to apply, and perceived as an added 
expenditure.  Older children and adolescents may not tolerate this treatment, seeing it as 
unattractive, time-consuming, and uncomfortable (27).  Additionally, due to the occlusive 
and wet nature of the wraps, discomfort and chills are to be expected, and folliculitis is a 
common adverse event.  Systemic bioactivity of corticosteroids as defined by prolonged 
suppression of the hypothalamus-pituitary-adrenal cortex axis and growth retardation has 
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not been reported in the published literature after short-term (2-14 days) intervention wet 
wrap treatment (28). 
Similar to wet wraps, soak and smear focuses on aggressively hydrating the skin, removal 
of scale and crust, and increasing the delivery of topical corticosteroids by application to wet 
skin.  Soaking functions to aid in exfoliation and creating a thinner and a more hydrated 
stratum immediately prior to topical corticosteroid application.  Smearing immediately after 
soaking presumably functions to trap moisture in the already wet stratum corneum and 
enhance delivery of the topical medication.  Studies have shown that higher levels of topical 
medications penetrate the dysfunctional epidermal barrier of AD than normal fully functional 
epidermal barrier (29). Additionally, topical medication penetrates moist stratum corneum 
10-100 times more than dehydrated stratum corneum (30). In contrast to wet wraps, soak 
and smear does not provide a physical barrier to scratching or act as an occlusive barrier.  
Although time intensive and messy, it is less so than wet wraps, as it cuts out the necessary 
steps of acquiring appropriately sized cotton bandages or pajamas, wetting them, and 
wrapping them around the child.  Soak and smear treatment has been shown to be highly 
effective in two studies in adults, one retrospective and one prospective. 
Previous Publications on Soak and Smear  
The first published report using the term “soak and smear” was a retrospective study of 28 
adults with difficult to treat eczema (approximately half with AD) who were instructed on the 
soak and smear protocol and underwent at-home nightly soak and smear therapy for a 
minimum of four days and a maximum of two weeks until their eczema had cleared.  Of the 
28 patients, 17 showed complete clearance, 9 showed more than 90% clearance, and 2 
showed more than 75% clearance.  After soak and smear treatment was discontinued, 
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patients were tapered down to applying ointment on without prior soaking, and finally to 
twice daily application of emollients (30). No long-term follow up was reported. 
In the second prospective study, seven deployed patients in the combat setting with severe 
flares of AD that had failed standard AD treatments underwent twice daily soak and smear 
for three days in the hospital setting using triamcinolone ointment over the entire body 
sparing the face and intertriginous areas.  At the end of three days, they were discharged 
and instructed to continue twice daily smears without prior soaking for 11 days.  On days 0, 
2, 7, and 14 they were evaluated by investigators for total body surface area affected, 
investigator global assessment (IGA) score, and patient self-assessment of AD and pruritus.  
Overall, more than 90% of patients responded with 90-100% clearance of disease.  All 
patients were noted to have substantial improvement by day 2 with a mean score of 1 on the 
IGAS as compared to a mean score of 4 on day 0.  Improvement in IGA score, patient self-
assessment of disease severity, and patient self-report of pruritus improved over the first 
seven days of treatment, and remained the same from day 7 to day 14 (31).  
Rationale 
To our knowledge, only two studies have investigated the efficacy of soak and smear for AD, 
both of which are described above and neither of which have studied soak and smear in the 
pediatric population.  Current application of soak and smear in the pediatric population is 
based primarily upon evidence from its success in the adult population, anecdotal reports, 
and expert opinion.  Only wet wrap dressings, which are similar in proposed mechanism of 
action to soak and smear, have been studied in the pediatric population, and their efficacy, 
although significant, has been less dramatic than what has been seen with soak and smear 
in the adult population.  In addition, wet wraps are tedious to apply and may encourage 
noncompliance and cause more stress to families and patients than soak and smear.  For 
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this reason, we believe that soak and smear may be a highly effective method of quickly 
gaining control of atopic dermatitis flares.  
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STATEMENT OF PURPOSE  
Primary Aim 
The primary aim of this study was to compare the efficacy of a soak and smear regimen for 
the application of topical corticosteroid ointment to the application of corticosteroid ointment 
applied without prior soaking (control) in children with atopic dermatitis.  The hypothesis was 
that the soak and smear regimen would be more efficacious than the control regimen for the 
treatment of atopic dermatitis in children.  Study subjects were less than 18 years of age, 
and the protocol included triamcinolone acetonide 0.1% ointment for patients 2 years of age 
or older or hydrocortisone 2.5% ointment for patients less than 2 years of age.  For patients 
in the experimental group, topical medication was applied to the face and intertriginous 
areas twice daily, once with soak and smear regimen and once without; control patients did 
not undergo the soaking procedure.  Efficacy was calculated using percentage improvement 
by the Eczema Area Severity Index (EASI) and by patient or caregiver assessment of 
disease severity and pruritus. 
Secondary Aims 
Secondary aims for this study were to investigate the influence of corticosteroid ointment 
application by soak and smear regimen versus standard regimen on hypothalamic-pituitary-
adrenal axis suppression and to quantify the level of corticosteroid ointment penetration 
through the skin by each regimen through serum cortisol levels. 
Additionally, this study sought to evaluate adverse events in each arm to determine if there 
would be any increased potential for harm in applying the medication employing the soak 
and smear regimen. 
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METHODS 
Contributors’ Statement 
Lucinda S. Liu designed and coordinated the study, collected data, and contributed to data 
analysis.  Yanna Kang analyzed the data.  Richard J. Antaya conceptualized and designed 
the study and contributed to data analysis. 
Study Design 
Patients two years of age or older were prescribed topical triamcinolone acetonide 0.1% 
ointment twice daily, and patients younger than two years of age were prescribed 
hydrocortisone 2.5% ointment twice daily.  All patients were prescribed hydrocortisone 2.5% 
ointment for facial and intertriginous areas. This medication regimen was part of the age-
appropriate standard of care healthcare provided to pediatric AD patients treated in the Yale 
Pediatric Dermatology Clinic.  Patients were randomized for method of application for the 
topical ointment.  The soak and smear arm employed the soak and smear regimen only 
during the evening application of corticosteroid ointment. 
If a patient was undergoing any treatment that requires the use of systemic corticosteroids, 
topical corticosteroids, or antibiotics, a washout period in which the medication was 
discontinued was required of the patient prior to participating in the study.  A washout period 
of two weeks was required if the patient was undergoing systemic corticosteroid therapy.  A 
washout period of one week was required of any patients who were undergoing topical 
corticosteroids therapy or systemic antibiotic treatment. 
The primary endpoint was the change in EASI score.  The secondary endpoints were the 
patient’s/guardian’s evaluation of disease severity, impact on sleep, and itch, adverse 
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effects reported by the patients/guardians or observed by the medical staff, and AM serum 
cortisol levels. 
Eligibility Criteria 
Patients were required to meet the following eligibility criteria: 
 1.  Patients must meet the clinical criteria of the American Academy of Dermatology 
Consensus Conference on Pediatric Atopic Dermatitis for the diagnosis of AD and 
have disease over at least 5% of their total body surface area. 
 2.  Patients less than 18 years of age. 
 3.  Families able to comprehend written instructions in English and able to complete 
questionnaires with assistance if needed. 
 4.  Parents/guardians able to understand and willing to sign a parental permission form.  
Children between the ages of 7-17 years will sign an age-appropriate assent form. 
Exclusion Criteria 
Patients who met any of the follow exclusion criteria were excluded from the study: 
 1.  Clinically infected AD. 
 2.  Patients who were allergic or intolerant of triamcinolone 0.1% ointment or 
hydrocortisone 2.5% ointment. 
 3.  Patients who did not have access to a bathtub. 
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Blinding  
The trial was blinded to Lucinda Liu who was responsible for all patient evaluations.  Richard 
Antaya, MD was not blinded and was responsible for demonstrating application of the drug 
to the patients or parents/guardians.  In order to maintain the blind, both the patient and the 
parent/guardian were instructed not to discuss the prescribed regimen with the blinded 
investigator. 
Randomization 
Patients were randomized in a form of restricted randomization known as random permuted 
blocks in which patients were randomized in blocks of either length four or six.  This allowed 
for the patients to be randomized maximally while maintaining a relatively equal number of 
participants in each arm.   In addition, because the blocks were of different lengths, and the 
lengths were randomized, there was less likelihood of the blinded investigator being able to 
predict the treatment regimen of the last patient in the block in the unlikely event that the 
blinded investigator was able to determine which patients were assigned to each arm for 
patients in a block (32). 
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Treatment Administration 
Treatment was administered on an outpatient basis.  On Day 0, all patients underwent a 
baseline history, which included demographic data, medical history, medication list, and 
personal and family history of AD, food allergies, asthma, and allergic rhinitis; physical 
exam; scoring of AD using EASI score, a patient self-assessment of disease severity and 
pruritus; and standardized digital photography of affected areas of the skin.  
All patients received a one-page handout that briefly explains AD and educates families on 
how to prevent further atopic dermatitis outbreaks (Appendix 1: Educational Hand-out).  The 
soak and smear arm received a page explaining the theory behind soak and smear and be 
given instructions on how to perform the soak and smear regimen (Appendix 2: Soak and 
Smear Instructions).  The control arm received a page explaining how to apply corticosteroid 
ointment for treatment of AD and specific instructions on bathing which requested caregivers 
to refrain from applying the topical corticosteroid to wet skin (Appendix 3: Standard Regimen 
Instructions). 
Patients/caregivers completed their therapies at home and documented progress, level of 
pruritus, level of sleep deprivation, and compliance at home daily in a handout that was 
provided to them at the initial visit (Appendix 3: Guardian Check Sheet). 
Both arms adhered to their respective regimens for two weeks, and then was assessed for 
clearance of AD.  For those patients in the standard regimen arm, if the patient’s AD had 
less than 75% clearance by EASI score, patients and their families/caregivers were offered 
to cross over into the soak and smear arm, and began the study again at Day 0 with a new 
baseline assessment followed by two weeks of the soak and smear regimen.  If the patient’s 
AD had more than 75% clearance by EASI score, patients and their families/caregivers 
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began maintenance therapy, which consisted of emollients and soap-free cleansers for 
bathing, and avoidance of harsh chemical detergents and fabric softeners.   
 Figure 1. Distribution of Patients 
Data Collection and Outcome Measures 
Assessment of AD by EASI score was conducted by the blinded investigator at baseline on 
Day 0 and Day 14 at the Yale Pediatric Dermatology Clinic.   
The main outcome measured was efficacy by EASI, which assessed AD disease severity 
based on level of dermatitis and body surface area involvement (33).  The EASI is based on 
four key aspects of AD that encompass both acute and chronic disease: erythema, 
induration/papulation, excoriation, and lichenification.  These aspects are scored and then 
weighted by the proportion of body surface area affected.  The EASI was chosen as the 
objective measurement of disease, because it has exhibited good inter-evaluator 
consistency, validity, sensitivity to change and correlated well with other validated measures 
of AD severity, such as the SCORAD (34).  
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The EASI assessment does not place value in any subjective measures of disease, such as 
level of pruritus or sleep loss.  In turn, itch score, overall impact of disease, and compliance 
were recorded by the patient or caregiver at daily at home for the following 14 days.  On Day 
14, patients and their caregivers returned to the Yale Pediatric Dermatology Clinic, and  
were asked to report adverse effects.  Digital photographs utilizing the same standard poses 
as baseline were also taken at this time.  
Patients and families that volunteered for giving blood samples were asked to submit a 
blood sample on Day 14.  On Day 0, all patients who have agreed to the blood draw were 
offered topical anesthetic (lidocaine 2.5%-prilocraine 2.5% cream) for application to the 
antecubital fossae one hour prior to the blood draw on Day 14 to decrease procedural 
discomfort.  Blood samples were drawn by phlebotomists at the Yale Center for Clinical 
Investigation (YCCI) laboratory.  Per the YCCI protocol, 1 ml of blood was drawn by 
venipuncture and stored in a lavender tube containing dipotassium 
ethylenediaminetetraacetic acid. Blood samples were sent to the YCCI Core Laboratory 
Services, and serum cortisol levels were processed in one batch by enzyme-linked 
immunosorbent assay using a radioimmunoassay kit.  Normal AM serum cortisol values 
were set by the manufacturer as 5-25 ug/dL (138-690 nmol/L). 
 Figure 2. Data Collection Flowchart 
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Sample Size Calculation 
To calculate our sample size, our null hypothesis was that there would be no difference in 
treatment results between the two arms. Predicted outcome for the soak and smear arm, 
which was measured by percentage improvement, was estimated from the two previous 
studies on soak and smear: 
Rustad and Henning (31) 
4 patients improved 100% 
1 patient improved 80% 
1 patient improved 75% 
1 patient improved 67% 
mean improvement=88.9% 
 
Gutman et al (30) 
17 patients improved 100% 
9 patients improved 95% 
1 patient improved 80% 
1 patient improved 75% 
mean improvement=96.8% 
 
From this, a weighted average of 95.2% improvement for the arm using soak and smear 
was calculated.  The predicted outcome size for standard treatment was estimated using a 
previous study that cited 60.5% improvement in patients with AD who applied triamcinolone 
0.1% ointment to dry skin twice daily for two weeks.  From this, the predicted effect size, 
defined as a difference in mean of outcome variables between two arms, was calculated to 
 27 
be 35%.  The standard deviation was then calculated to be 13.3 / (47.6 – 18.8) = 0.45.  
From this, the standardized effect size was calculated by dividing 35 by 45, which is 0.78.  
For this study to detect a difference of at least 15% (by objective EASI score) between the 
two treatment arms, with an estimated standard deviation of 20%, and using a two-sided t 
test with α (two-sided)=0.05, we required a sample size of 26 participants in each arm to 
reach 80% power (35).    Estimating a drop out rate of 5%, we calculated a need for 55 
participants total to reach significant power. 
Statistical Analysis 
A two-sided Wilcoxin rank sum test was used over the unpaired t-test for the following 
reasons: the subjects of the two arms are independent samples but cannot be assumed to 
be normally distributed, and the sample size is small (36).  The null hypothesis was that the 
mean percentage improvement by EASI score in the treatment arm (soak and smear) is the 
same as that in the control arm.  Whereas, the alternative hypothesis was that the mean 
percentage improvement by EASI score in the two arms are different.  The formula used to 
calculate mean percentage difference by EASI score is as follows: if patient A scored an 
initial EASI score of A1 and a final EASI score of A2, and patient B scored an initial EASI 
score of B1 and a final EASI score of B2, the mean percent age difference was calculated 
by the formula [(A1 – A2)/A1 + (B1 – B2)/B1]/2.  
Investigative Review Board Approval and ClinicalTrials.gov Registration 
This study was approved by the Yale Pediatric Protocol Review Committee and Yale Human 
Research Protection Program (HRPP), formerly known as the Human Investigation 
Committee of Yale School of Medicine, in June 2012.  This study was also posted on 
ClinicalTrials.gov in August 2012 and has the identifier NCT01675232. 
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RESULTS  
Demographics and Baseline Comparisons 
Between July 2012 and July 2013, 46 patients with atopic dermatitis presented to the Yale 
Pediatric Dermatology clinic who were eligible for our study.  Of these, 45 patients enrolled 
in our study.  Every patient had been referred from either their general pediatrician or 
community dermatologist.   
Table 3: Demographics 
*p-value calculated by Fisher’s exact test. **p-value calculated by chi-square test. 
 CONTROL SOAK AND SMEAR Wilcoxin 
Patients 23 24  
Age in years mean ± SD (range) 3.1 ± 4.0 (0.3 - 16) 3.2 ± 3.4 (0.3 - 11) p = 0.8 
Gender female : male 8 : 15 10 : 12 p = 0.18* 
Race   p = 0.28** 
Caucasian 14 12  
Black 2 5  
Asian 5 2  
Hispanic 0 2  
Other 2 1  
Initial EASI mean ± SD (range) 15.1 ± 6.9 
(2.8, 29.7) 
15.8 ± 9.1 
(4.6, 34.95) 
p = 0.9 
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All 45 patients, 22 in the soak and smear arm and 23 in the control arm, returned for their 
14-day follow-up visit.  Two patients were originally enrolled in the control arm and 
subsequently crossed over into the soak and smear arm after two weeks of treatment.  
Patients ranged from 4 months of age to 16 years of age, with an average of 3.2 and 3.1 
years of age in the soak and smear and control arms, respectively. The mean EASI score 
was 15.8 and 15.1 in the soak and smear and control arms, respectively.  Demographic 
characteristics are further delineated in Table 3. 
Efficacy by Eczema Area and Severity Index 
Patients in the soak and smear arm showed a mean reduction in EASI score from baseline 
of 84.8% ± 16.5%, from a mean initial EASI score of 15.8 ± 9.1 to a mean final EASI score 
of 2.5 ± 3.5 at the two-week visit.  Patients in the standard arm showed a mean reduction in 
EASI score from baseline of 81.4% ± 25.6%, from a mean initial EASI score of 15.1 ± 6.9 to 
a mean final EASI score of 2.6 ± 4.3 at the two-week visit.  There was no difference between 
the soak and smear arm and the standard treatment arm (p = 0.85) (Table 4). 
Table 4: Outcomes by EASI Score 
 INITIAL EASI 
mean ± SD (range) 
FINAL EASI 
mean ± SD (range) 
% DIFFERENCE 
mean ± SD (range) 
Wilcoxin 
CONTROL 15.1 ± 6.9 
(2.8, 29.7) 
2.6 ± 4.3 
(0, 19.1) 
81.4 ± 25.6 
(0.5, 100) 
p = 0.85 
SOAK AND 
SMEAR 
15.8 ± 9.1 
(4.6, 34.95) 
2.5 ± 3.5 
(0, 13.5) 
84.8 ± 16.5 
(40.2, 100) 
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Given that there was no statistically significant difference in outcome by EASI score 
between the soak and smear and standard treatment arms, the question was asked whether 
the soak and smear method would benefit patients with more severe AD.  The two arms 
were then stratified into mild, moderate, and severe subgroups by EASI score, which was 
adopted from a previously published stratification model by Eichenfield et al (37).   Patients 
with EASI scores of 8 or less were categorized as mild; those with EASI scores of greater 
than 8 to 15 were categorized as moderate; and those with EASI scores of greater than 15 
were categorized as severe.  Overall, nine patients were stratified into the mild AD subgroup 
by their initial EASI score, of which four patients were randomized to the soak and smear 
arm.  Twenty patients were stratified into the moderate AD subgroup by their initial EASI 
score, of which nine were randomized to the soak and smear arm.  Finally, eighteen patients 
were stratified into the severe AD subgroup by their initial EASI score, of which nine were 
randomized to the soak and smear arm. 
Patients who had severe AD and who were randomized to the soak and smear arm showed 
a mean reduction in disease severity of 83.0% ± 19.4% by EASI score.  Patients who had 
severe AD and who were randomized to the control arm showed a mean reduction in 
disease severity of 80.9% ± 32.7% by EASI score.  Once again, there was no statistically 
significant difference between the two treatment arms for those with severe AD (p = 0.39) 
(Table 5). 
Patients who had moderate AD and who were randomized to soak and smear showed a 
mean reduction in disease severity of 84.4% ± 17.0% by EASI score.  Patients who had 
moderate AD and who were randomized to control showed a mean reduction in disease 
severity of 81.9% ± 24.0% by EASI score.  There was no statistically significant difference 
between the two treatment arms for those with moderate AD (p = 0.57) (Table 5). 
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Patients who had mild AD and who were randomized to soak and smear showed a mean 
reduction in disease severity of 89.7% ± 9.2% by EASI score.  Patients who had moderate 
AD and who were randomized to control showed a mean reduction in disease severity of 
81.1% ± 7.95% by EASI score.  There was no statistically significant difference between the 
two treatment arms for those with mild AD (p = 0.23) (Table 5). 
Table 5: Outcomes by EASI Score Stratified by Disease Severity 
 INITIAL EASI 
mean ± SD 
(range) 
FINAL EASI 
mean ± SD 
(range) 
% DIFFERENCE 
mean ± SD 
(range) 
Wilcoxin 
Severe AD CONTROL 22.2 ± 4.2 
(16.6, 29.7) 
3.99 ± 6.4 
(0.15, 19.1) 
80.9 ± 32.7 
(0.52, 99.5) 
p = 0.39 
SOAK AND 
SMEAR 
25.2 ± 5.95 
(15.35, 34.95) 
4.2 ± 4.8 
(0.5, 13.45) 
83.0 ±  19.4 
(40.2, 97.96) 
Moderate AD  CONTROL 11.9 ± 2.3 
(8.7, 14.95) 
2.0 ± 2.3 
(0, 7.9) 
81.9 ± 24.0 
(14.1, 100) 
p = 0.57 
SOAK AND 
SMEAR 
10.5 ± 2.0 
(8.1, 15) 
1.6 ± 1.7 
(0, 4.8) 
84.4 ± 17.0 
(48.7, 100) 
 Mild AD 
CONTROL 5.6 ± 2.4 
(2.8, 7.35) 
0.93 ± 0.28 
(0.75, 1.25) 
81.1 ± 7.95 
(73.2, 89.1) 
  p = 0.23 
SOAK AND 
SMEAR 
6.3 ± 1.8 
(4.6, 7.9) 
0.74 ± 0.75 
(0, 1.75) 
89.7 ± 9.2 
(77.6, 100) 
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Efficacy as Measured by Pruritus 
During the 14-day treatment, each caregiver or patient was instructed to assign a daily value 
to the patient’s level of pruritus on a scale of 0 to 10, with 0 indicating no itch and 10 
indicating severe itch.  Patients in the soak and smear arm had a mean baseline itch score 
of 6.3 ± 2.9, which improved by 39.0% ± 91.7% to 2.9 ± 2.3  by Day 7 and by 77.8% ± 
20.6%  to 1.6 ± 1.9 by Day 14.  Patients in the standard treatment arm had a mean baseline 
itch score of 5.4 ± 3.0, which improved by 48.8% ± 44.6% to 2.7 ± 2.7 on Day 7 and by 
75.8% ± 28.0% to 1.9 ± 2.8 by Day 14.  There was no statistically significant difference  in 
itch improvement level between the two treatment arms on Day 7 (p = 0.83) or Day 14 (p = 
0.85) (Table 6). 
Table 6: Outcomes by Pruritus Score 
 DAY 1 
mean ± SD 
DAY 7  
mean ± SD  
(% diff ± SD) 
Wilcoxin DAY 14  
mean ± SD  
(% diff ± SD)  
Wilcoxin 
CONTROL 5.4 ± 3.0 2.7 ± 2.7  
(48.8 ± 44.6) 
p = 0.83 
1.9 ± 2.8  
(75.8 ± 28.0) 
p = 0.85 
SOAK AND 
SMEAR 
6.3 ± 2.9 2.9 ± 2.3  
(39.0 ± 91.7)  
1.6 ± 1.9  
(77.8 ± 20.6) 
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Efficacy as Measured by Overall Impact of Disease 
During the 14-day treatment, each caregiver or patient was instructed to assign a daily value 
to the overall impact of disease, which was explained to each patient and caregiver as how 
much the AD affected sleep, itch, appearance, and overall quality of life, and was rated on a 
scale of 0 to 10, with 0 indicating no effect on quality of life and 10 indicating a miserable 
quality of life due to AD.   
Patients in the soak and smear arm had a mean baseline overall impact of disease score of 
7.2 ± 2.1, which improved by 52.3% ± 34.3% to 3.1 ± 1.9 by Day 7 and by 64.8% ± 44.0% to 
2.2 ± 2.7 by Day 14.  Patients in the standard treatment arm had a mean baseline overall 
impact of disease score of 5.0 ± 3.0, which improved by 54.1% ± 35.7 % to 2.9 ± 2.6 on Day 
7 and by 74.0% ± 28.7% to 2.0 ± 2.6 by Day 14.  There was no statistically significant 
difference in impact of disease score improvement between the two treatment arms on Day 
7 (p = 0.8) or Day 14 (p = 0.6) (Table 7). 
Table 7: Outcomes by Overall Impact of Disease 
 DAY 1 
mean ± SD 
DAY 7  
mean ± SD  
(% diff ± SD) 
Wilcoxin DAY 14  
mean ± SD  
(% diff ± SD) 
Wilcoxin 
CONTROL 5.0 ± 3.0 2.9 ± 2.6 
(54.1 ± 35.7) 
p = 0.8 
2.0 ± 2.6  
(74.0 ± 28.7) 
p = 0.6 
SOAK AND 
SMEAR 
7.2 ± 2.1 3.1 ± 1.9 
(52.3 ± 34.3) 
2.2 ± 2.7  
(64.8 ± 44.0) 
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Efficacy as Measured by Sleep 
During the 14-day treatment, each caregiver or patient was instructed to assign a daily value 
to the overall quality of sleep, which was rated on a scale of 0 to 3, with 0 indicating that the 
patient slept well and 3 indicated that the patient slept poorly. 
Patients in the soak and smear arm had a mean baseline sleep score of 1.3 ± 1.1, which 
improved by 59.0% ± 40.0% to 0.6 ± 0.8 by Day 7 and by 62.5% ± 43.9% to 0.5 ± 0.7 by 
Day 14.  Patients in the standard treatment arm had a mean baseline sleep score of 1.3 ± 
1.1, which improved by 54.7% ± 59.4% to 0.7 ± 0.7 by Day 7 and by 54.4% ± 48.2% to 0.7 ± 
0.8 by Day 14.  There was no statistically significant difference in sleep score improvement 
between the two treatment arms on Day 7 (p = 0.9) or Day 14 (p = 0.7) (Table 8). 
Table 8: Outcomes by Sleep Score 
 DAY 1 
mean ± SD 
DAY 7  
mean ± SD  
(% diff ± SD) 
Wilcoxin DAY 14 
mean ± SD  
(% diff ± SD) 
Wilcoxin 
STANDARD 1.3 ± 1.1 0.7 ± 0.7 
(54.7 ± 59.4) 
0.9 
0.7 ± 0.8 
(54.4 ± 48.2) 
0.7 
SOAK AND 
SMEAR 
1.3 ± 1.1 0.6 ± 0.8 
(59.0 ± 40.0) 
0.5 ± 0.7 
(62.5 ± 43.9) 
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Compliance 
During the two weeks of study participation, patients were relatively compliant to their topical 
corticosteroid application regimens.  This was recorded on the caregiver worksheet, which 
asked caregivers or patients to record on a daily basis whether or not they were able to 
adhere to the treatment intervention.  On average, patients randomized to the soak and 
smear arm missed 0.67 ± 1.09 days of the 14-day intervention.  In comparison, patients 
randomized to the control arm missed on average 0.48 ± 0.59 days of topical corticosteroid 
application.  There was no statistically significant difference between the compliance rate of 
the two study arms (p = 0.8) (Table 9). 
Table 9: Study Compliance 
 Mean Number of Days missed ± SD Wilcoxin 
CONTROL 0.48 ± 0.59 
p = 0.8 
SOAK AND SMEAR 0.67 ± 1.09 
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Serum Cortisol Levels 
Of the 45 patients enrolled, ten elected to participate in a voluntary AM serum cortisol level 
draw.  All patients had their blood drawn between 8:15 AM and 8:45 AM.  Nine of the 
patients had AM serum cortisol levels within the normal range (Table 10).  One patient, who 
was in the standard treatment arm, had a serum cortisol level of 4.75 ug/dL, which is under 
the lower limit of normal (5 ug/dL). 
Table 10: AM Serum Cortisol Levels 
 STANDARD SOAK AND SMEAR Wilcoxin 
AM Cortisol (ug/dl) 12.35 (4.75 - 22.15) 14.98 (7.01 - 21.47) p = 0.61 
 
Adverse Events 
Three patients in the soak and smear arm and five patients in the standard treatment arm 
developed folliculitis.  No patients in this study developed visible signs of skin atrophy, such 
as wrinkling, thinning or depression, increased venous pattern, striae, or increased skin 
fragility.  No patients in this study developed any other local adverse effects such as 
rosacea, acne, contact dermatitis or changes in pigmentation.  No patients developed signs 
of systemic suppression of the hypothalamic pituitary adrenal axis, such as moon facies, fat 
redistribution, signs or symptoms of glucose intolerance or immunosuppression. 
Early Termination of the Study 
Although every attempt was made to recruit to our original sample size of 52 patients, our 
study was terminated early due to investigator-related constraints on time.  We were 
reassured in ending our study at 45 patients after re-estimation of the sample size by 
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calculating a futility assessment with conditional power (38, 39).  The calculated conditional 
power was calculated based on data gathered after accruing 45 patients.  From these data, 
the conditional power was calculated to be 0.05, which means that, given the data we have 
accrued so far, there was only 5% chance of rejecting the null hypothesis and concluding 
that there is statistically significant difference between the two arms.  From these 
conclusions, we found it unnecessary to recruit 52 patients suggested by our original power 
calculation and terminated the study after recruiting 45 patients. 
Crossover Group 
Three patients were asked to cross over from the control arm into the soak and smear arm 
due to a clearance by EASI score of less than 75%, and of those, and of those, two returned 
for their second 14-day follow-up visit.  The family who did not return reported difficulty in 
keeping the follow-up appointment due to parent work schedule and frustration with lack of 
AD clearance.  Of the two who followed up after crossing over, one improved with 98% 
clearance, and one improved with 27% clearance in AD severity. 
The data was reanalyzed with the addition of the data from the two patients that had 
crossed over from the control arm into the soak and smear arm.  All of the above results 
remained similar in that there remained no change in statistical significance between the two 
arms.   
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DISCUSSION 
This study shows that twice-daily application of topical corticosteroid ointment over a period 
of two weeks results in a considerable improvement in AD severity using either soak and 
smear or standard topical corticosteroid application techniques.  In the two arms studied 
there was no difference in the degree of AD improvement by EASI score, pruritus, or overall 
impact of disease at two weeks.  Moreover, there was no difference between the two 
interventions in the more severe AD subgroup or in the moderate AD subgroup.   
The Theory of Soak and Smear 
Atopic dermatitis is the most common inflammatory skin disease in children, and its 
pathology is thought to arise from a defect in skin barrier and abnormal immune 
responsiveness.  In theory, soak and smear seems like an effective intervention, combining 
both intensive hydration to repair the barrier with topical corticosteroid medication to reduce 
inflammation.  Furthermore, soaking effectively exfoliates the skin, which then aids topical 
corticosteroid penetration.  Smearing on ointments then traps the moisture in the stratum 
corneum and delivers the anti-inflammatory medication where the disease is located.  It is 
this theory that has led to soak and smear’s wide acceptance by the dermatology 
community for treatment of AD and other dermatitis in adults and children despite the limited 
rigorous studies on its efficacy and absence of studies on its efficacy in the pediatric 
population.  The two studies that were previously published on the efficacy of soak and 
smear for AD, although promising in their support of soak and smear for recalcitrant AD, 
were limited in their design.   
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Limitations of Previous Studies on Soak and Smear 
The Gutman et al study published in 2005 was retrospective, and as all retrospective studies 
are in their nature, it was not controlled.  For example, length of intervention ranged from 
several days to two weeks and the method of assessing AD severity and improvement was 
not a well-validated rubric (only by an undefined “percent response” as rated by both the 
physician and patient).  The intervention in this study was identical to the one we enacted in 
ours: one nightly soak in lukewarm plain water prior to topical corticosteroid application to 
wet skin.  Additionally, all the patients in this study were adults with ages that ranged from 
24 to 84 years of age, which does not translate well to the pediatric population that carries 
the burden of disease in AD.  Finally, only 15 of 28 patients had AD, whereas the others had 
psoriasis, xerotic eczema, nummular eczema, and irritant dermatitis.   
A prospective study conducted by two physicians in the army was subsequently conducted 
and verified the successful results of the 2005 retrospective study.  In this study, seven 
deployed soldiers in the combat setting who had severe recalcitrant AD who had failed 
outpatient topical corticosteroids were hospitalized for three days and underwent soak and 
smear intervention twice daily.  This intervention differed from the one in our study, because 
it was a twice daily soak rather than one nightly soak.  Several confounders interfered with 
the validity of the study results claiming that soak and smear was more effective than 
standard therapy.  First, all seven patients were removed from their combat setting, which 
was likely a stressful situation to be in and filled with combat debris, and were moved to a 
controlled hospital setting away from the stress and allergens associated with combat.  
Previous studies have shown that hospitalization alone may improve the severity of AD (40). 
Patients in this study underwent direct observed therapy in the hospital setting, another 
intervention that was not available while the soldiers were in the combat setting.  Like the 
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Gutman et al study, there was no control arm in this study, which makes it difficult to 
conclude that soak and smear is superior to standard treatment.  Finally, in both studies, 
patients were newly referred to these providers, which raises the question of whether it was 
the care of a new provider or the soak and smear intervention itself that motivated dermatitis 
clearance.   
It is possible that the remarkable improvement in disease severity in both prior studies is 
truly attributable to the soak and smear intervention and that soak and smear simply does 
not apply as well to the pediatric population.  The patients in these prior studies all reported 
failing multiple treatments and having recalcitrant skin disease.  They were also older and 
most likely had drier skin than most pediatric AD patients.  It could be postulated that soak 
and smear is an effective intervention for specific populations, namely those with severe 
disease that is proven to be recalcitrant to adequate topical corticosteroid therapy and/or 
those with xerotic forms of pruritic dermatitis such as those patients with filaggrin mutations 
such as ichthyosis vulgaris. This trial did not take into account the presence of ichthyosis 
vulgaris in our subjects.   
Treatment Adherence and the Role of Patient Education 
The negative results of this study may initially seem unexpected given the overly positive 
results of the previous two studies described above as well as the wide acceptance of using 
soak and smear as a treatment technique for AD.  There are several reasons that may 
explain why the patients who participated in both arms improved remarkably and at the 
same percentage by EASI score.  All of our families benefitted from careful patient 
education regarding appropriate preventive and therapeutic measures.  Preventative 
measures included proper skin lubrication during non-flared states, removal of irritants in the 
environment such as non-cotton clothing and bedding, and removal of irritant detergents, all 
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of which serves to prevent future AD flares.  Education regarding therapeutic measures to 
control current AD flares was mainly geared towards application of sufficient volume of 
topical corticosteroid medication and maintaining the correct duration of treatment.   
Nearly all of our patients presented to our clinic with some level of reluctance towards using 
adequate amounts of topical corticosteroids.  It was clear when caregivers would describe 
the quantity of topical corticosteroid they had applied under the direction of their previous 
health provider, that they were not applying sufficient quantities of medication to their 
affected skin.  This is not surprising, since studies have shown that 60-73% of patients or 
parents have a fear of or anxiety towards using topical corticosteroids, which subsequently 
leads to under-treatment and poor treatment adherence (41, 42).  This phenomenon, 
referred to by some as “topical corticosteroid phobia,” is thought to stem from 
misunderstanding about the nature of topical corticosteroids.  Media publicity, 
misconceptions that corticosteroids are related to anabolic steroids, and excessive 
precaution from primary care providers often will lead patients to use inadequate volume of 
topical corticosteroids or to simply avoid treatment with topical corticosteroids.  As with all 
misconceptions, the most effective method to address them is with education.  Although 
many of our participants initially presented with a fear of using topical corticosteroids, all of 
them were willing to treat with appropriate volume of topical corticosteroids and for the full 
treatment duration of two weeks once they received the appropriate education. 
Moreover, a great amount of information is exchanged during the clinic encounter, and the 
method in which teaching is conveyed is also important for patient/caregiver education.  In 
an effort to encourage treatment adherence, patients received both verbal in-person 
teaching about maintenance and flare treatment of their AD, but also written handouts with 
the same information.  Written action plans have been shown to increase adherence and 
decrease the number of visits to the emergency department in children with asthma; 
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however, no studies have looked at the utility of written action plans for children with AD (43). 
Theoretically, a written hand-out reiterating important treatment concepts is critically 
important to patient care as it communicates the same information in a different method, 
clarifies common questions caregivers may have, reminds families to participate in 
treatment, and helps them navigate changes in treatment.  Several studies have shown that 
time spent educating patients and their caregivers decreased disease severity and improved 
quality of life (43).   
In addition to careful education on the benefits and adverse effects associated with the use 
of topical corticosteroids for the treatment of AD, our patients were also provided with ample 
amount of topical corticosteroids.  This most likely played a huge role in AD disease 
clearance as it has been shown that patients who apply the correct amount of topical 
corticosteroid to AD skin showed a statistically significant improvement in disease severity 
(44).  While not directly measured in this study, it was observed that the majority of subjects 
referred to the pediatric dermatology clinic with AD had been prescribed an amount of 
topical steroid insufficient to successfully cover the affected areas for a 2-week course. 
When insurance policies would allow it and pharmacies had it in stock, patients used one-
pound jars of hydrocortisone 2.5% or triamcinolone 0.1% ointment.  When one-pound jars 
were not available due to financial or supply reasons, patients were still given a one-pound 
equivalent of corticosteroid ointment via multiple tubes.  Patients were provided with an 
estimate as to how much corticosteroid ointment they should have applied by the end of the 
two-week study intervention, adding further incentive to adhere to the appropriate topical 
corticosteroid regimen. 
Lastly, our patients were very compliant with our recommended treatment schedule and 
amount of topical corticosteroid applied, which contradicts previous studies showing that 
pediatric patients with AD are in fact very noncompliant with therapy.  For example, a 2007 
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study using microprocessor stealth monitoring of medication use showed an abysmal 32% 
adherence to therapy (45).  Our study’s remarkably high compliance could be due to a 
variety of factors.  The biggest one is the Hawthorne effect: by their being in a study, our 
patients knew that they were being observed and changed their behavior to accommodate.  
Additionally, in this study, every patient was called after one week to assess for adverse 
effects but to also encourage compliance (46).  Finally, it has been shown that patients 
become more adherent to treatment before and after a visit to the doctor.  The short follow-
up time of two weeks in our study also likely encouraged treatment adherence. 
Adverse Effects 
The systemic absorption of steroids and possible effects on the hypothalamic-pituitary-
adrenal axis is negligible for a two-week time span.  Although many clinicians have 
postulated that a fully hydrated epidermis allows for better penetration of topical medications, 
in our experience, a well-hydrated epidermis followed by liberal application of topical 
corticosteroids did not result in suppression of the adrenal axis. 
Study Limitations 
The biggest limitation of the study was due to study participant number.  Our initial power 
calculation suggested that we would need 52 total participants, yet we only recruited 45 
patients.  This was mainly due to slower than expected recruitment, but also because of the 
results of an interim analysis.  Additionally, this study’s small numbers limits its ability to 
detect a subset of the population who might have benefitted from soak and smear, as shown 
by the patient in the crossover group who cleared remarkably with soak and smear, but did 
not with standard treatment.  It would be difficult to draw any conclusions from the 
characteristics of the three patients in the crossover group given their small number; 
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however, in looking back through their photos, none of them had ichthyosis vulgaris.  
Further, given its limited numbers, it would have been difficult to stratify our patients by such 
traits like very severe AD and ichthyosis vulgaris in an effort to confirm, isolate, and 
characterize a population that could benefit from soak and smear. 
It should also be noted that patients in the soak and smear arm underwent the soak and 
smear regimen only once per day in the evenings and applied topical corticosteroid to dry 
skin in the mornings.  Thus, it cannot be concluded that performing the soak and smear 
regimen twice daily would be superior to twice daily control regimen. 
Finally, although caregivers were thoroughly educated on how to practice soak and smear, 
no clinician or study coordinator directly observed the soak and smear therapy regimen.  
Children can often be energetic and mobile during bathtime, and may not be able to soak 
themselves in a bathtub as thoroughly and consistently as an adult would be able to. 
Conclusions 
This prospective, investigator-blinded, randomized controlled study shows that two weeks of 
soak and smear is not more effective than two weeks of application of topical corticosteroid 
to dry skin in children for the treatment of atopic dermatitis.  Instead, both arms—soak and 
smear and control— showed equivalent clearance rates as assessed by the objective EASI 
score.  Both interventions displayed remarkably high clearance rates of disease.  Our 
patients were referred to us from their pediatricians or community dermatologists and had 
originally failed therapy from these first-line medical providers.  The undiscriminating 
improvement in AD clearance can most likely be attributed to the other interventions 
provided in this study, mainly education, which alleviated steroid phobia, a phone call after 
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one week, which encouraged patients to continue adhering to therapy, and homework, 
which reminded patients and caregivers on a daily basis to adhere to treatment. 
Future Directions 
This study is the first to dispute the efficacy of soak and smear, and larger studies are 
needed to further validate its claim.  Additionally, if the results of this study are indeed true, 
then in vivo studies on the effect hydration has on the penetration of topical medications 
through the epidermal barrier are warranted to further assess drug penetrance through the 
epidermal barrier.  It is also possible that soak and smear does indeed enhance skin 
hydration and topical drug delivery, and that the two-week endpoint selected for our study 
was unnecessarily long and allowed the control arm to catch up in terms of efficacy.  A 
future study with a shorter treatment period of one week would help clarify this possibility.  
From asking caregivers about the quantity of topical corticosteroid they used for AD 
treatment at the time of initial presentation to our clinic, we suspected that most of our 
patients had failed topical corticosteroid from their pediatrician because they were applying 
inadequate amounts of topical medication.   A future study quantifying the effect that 
quantity of topical corticosteroid has on the clearance rate of atopic dermatitis in children 
should also be performed. 
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APPENDIX   
Appendix 1: Educational Hand-out 
Maintenance Treatment: Strategies to Prevent Further Outbreaks 
1. Apply fragrance-free moisturizer on slightly moist skin after showering or washing hands 
Repeated wetting (i.e., baths, showers, swimming) without moisturization will actually dry out 
the skin more.  Less thick moisturizers may be used during the daytime, with petroleum jelly 
or petroleum jelly based moisturizers always available for more intense moisturization at 
night.  
Recommended Moisturizers 
• Cetaphil cream 
• CeraVe Cream 
• Aveeno for extra dry skin 
• Aveeno eczema therapy 
• Eucerin Cream 
• Aquaphor Ointment 
• Vaseline petroleum jelly 
• Theraplex Emollient 
 
 Light moisturizers 
 
 
 
Heavy moisturizers 
2. Limit the use of cleansers to armpits and groin 
Try to use cleansers rather than soap.  Using cleansers in the shower can further dry out the 
skin by removing the oils the skin naturally produces.  You can get clean and help your skin 
by limiting the use of cleansers to the armpits and groin.   
Recommended Soap-free Cleansers 
• Cetaphil 
• Cetaphil restoraderm 
• Aquanil 
• Neutrogena 
• CeraVe cleanser 
• Unscented Dove 
 
3. After bathing, gently pat dry 
Be careful not to rub the skin, which can be thought of as scratching in disguise. 
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Appendix 2: Soak and Smear Instructions 
Soak and Smear Patient Educational Instruction Sheet 
Atopic Dermatitis (AD) 
AD (or eczema) is a chronic condition of the skin that can cause itchiness and redness. 
Children with AD have sensitive skin, more sensitive than normal skin.  Sensitive skin is 
more easily irritated (which causes the itchiness) by dryness and irritants in the environment 
(such as wool in clothing or certain detergents). AD can be controlled with good skin care 
and environmental measures (avoiding things that irritate your skin). 
 
Soaking and Smearing 
This is an aggressive treatment that is messy (find an old pair of pajamas) and slightly time 
intensive. This regimen may use a medication you have used before without success. But 
this medicine is being used in a different way as part of an intensive treatment regimen that 
must be followed exactly to work. This treatment can lead to marked improvement in even a 
couple of days. 
The soaking will allow water to go into the skin and hydrate it, then smearing on the 
ointment will  
1) trap water in the skin (because water cannot move through oil) and moisturize the skin  
2) allow the medication to absorb  into the skin better. 
Usually patients do the soaking and smearing at night for 2 weeks.  
The soaking and smearing treatments are done at night because the ointment on your skin 
will get on your pajamas instead of your clothes (that you wear during the daytime) and the 
ointment will be on your skin for several hours while you sleep.  You may wish to use an old 
pair of pajamas, older sheets/blankets and even make use of a mattress pad during this 
treatment to protect your bed from the excessive oil.  
 
Soak in a bath (not a shower) in plain, lukewarm water for 10 minutes (use a timer) at 
night, THEN immediately without drying the skin smear, , on the corticosteroid ointment. 
This should be done nightly for 14 days. 
 
Throughout the treatment period you should apply the medication to the affected areas 
in the morning on dry skin (i.e. not using the soak and smear method) 
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Appendix 3: Standard Regimen Instructions 
Standard Care Patient Educational Instruction Sheet 
Atopic Dermatitis (AD) 
AD (or eczema) is a chronic condition of the skin that can cause itchiness and redness. 
Children with AD have sensitive skin, more sensitive than normal skin.  Sensitive skin is 
more easily irritated (which causes the itchiness) by dryness and irritants in the environment 
(such as wool in clothing or certain detergents). AD can be controlled with good skin care 
and environmental measures (avoiding things that irritate your skin). 
 
The corticosteroid ointment will simultaneously  
1) moisturize your skin and keep it from drying out  
2) decrease the itch that you may feel, help you scratch your skin less 
 
How to apply your medication ointment 
Usually patients apply their corticosteroid ointment twice daily, once in the morning, once at 
night for 2 weeks.  Throughout the treatment period you should apply the medication to the 
affected areas on dry skin.  If applying after a bath or shower, wait at least 15 minutes until 
the skin is dry before applying the corticosteroid ointment.  DO NOT apply the corticosteroid 
ointment to wet skin. 
 
 
 
 
 
   
 52 
Appendix 4: Guardian Check Sheet 
ECZEMA CHECK SHEET 
 
WEEK 1 
DAY:        
Did you do the treatment regimen?        
How did you sleep?  (0-3)        
Itch level  (0-10)        
Overall assessment  (0-10)        
 
WEEK 2 
DAY:        
Did you do the treatment regimen?        
How did you sleep?  (0-3)        
Itch level  (0-10)        
Overall assessment  (0-10)        
 
 
 
